[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Assembly Biosciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100651656","phase-2-a-study-to-assess-the-safety-pharmacokinetics-and-efficacy-of-abi-6250-in-participants-with-chronic-hepatitis-d-virus-infection-100651656",false,"NCT07762027","A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection","A Phase 2, Multicenter, Open Label, Parallel-Group Study of the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection","Inclusion Criteria:\n\n* Participant has a body mass index ≥18.0 and \\\u003C35.0 kg\u002Fm2 at Screening\n* Other than HBV and HDV infection, the participant is in good health (as determined by the Investigator) based on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory results.\n* Participant agrees to comply with protocol-specified contraception requirements.\n\nExclusion Criteria:\n\n* Participant has a current coinfection with acute hepatitis A virus (HAV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).\n* Participant has a history of any significant food or drug-related allergic reactions such as anaphylaxis, Stevens-Johnson syndrome, or urticaria.\n* Participant has been treated for HDV infection in the past 6 months prior to Day 1.\n* Participant took part in another clinical trial of a drug or device (other than for HDV infection) whereby the last study drug\u002Fdevice administration is within 30 days or 5 half-lives, whichever is longer, prior to Day 1.","ALL","18 Years","70 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.",[27],"Chronic Hepatitis D Infection","NOT_YET_RECRUITING","2026-08-07",{"date":31,"type":32},"2026-08-13","ACTUAL",{"date":34,"type":21},"2026-10",{"date":36,"type":21},"2028-09",{"name":38,"class":39},"Assembly Biosciences","INDUSTRY",22,""]